Ca2+ channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats

Journal of Hypertension

Volumn 28, Issue 7, 2010, Pages 1515-1526

  Nishizawa, Takao ^a   Cheng, Xian Wu ^a,f,g   Jin, Zhehu ^b,f   Obata, Koji ^c   Nagata, Kohzo ^d   Hirashiki, Akihiro ^a   Sasaki, Takeshi ^b   Noda, Akiko ^d   Takeshita, Kyosuke ^a   Izawa, Hideo ^a   Shi, Guo Ping ^e   Kuzuya, Masafumi ^b   Okumura, Kenji ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e HARVARD MEDICAL SCHOOL   (United States)

^f YANBIAN UNIVERSITY   (China)

^g Kyung Hee University College of Medicine   (South Korea)

Author keywords

angiogenesis; cardiac stiffness; diastolic heart failure; hypoxiainduced factor

Indexed keywords

BENIDIPINE; CALCIUM CHANNEL T TYPE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; NITRENDIPINE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD VESSEL DIAMETER; CAPILLARY DENSITY; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HYPERTENSION; KIDNEY FIBROSIS; LUNG WEIGHT; MALE; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SALT INTAKE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

EID: 77954387358     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328339fd3a     Document Type: Article

References (45)

1. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, et al. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18:111-120.
2. Cheng XW, Okumura K, Kuzuya M, Jin Z, Nagata K, Obata K, et al. Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol 2009; 54:47-56.
3. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33:1948-1955.
4. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
5. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa N, Kondo H, et al. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 2000; 36:2333-2338.
6. Angeja BG, Grossman W. Evaluation and management of diastolic heart failure. Circulation 2003; 107:659-663.
7. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17:590-596.
8. Yamamoto E, Lai ZF, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006; 24:2057-2069.
9. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43:263-269.
10. Hermsmeyer K, Mishra S, Miyagawa K, Minshall R. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists. Clin Ther 1997; 19:18-26.
11. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension 2001; 38:343-347.
12. Van der Vring JA, Cleophas TJ, Van der Wall EE, Niemeyer MG. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group. Am J Ther 1999; 6:229-233.
13. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, Hanck DA. Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 2000; 295:302-308.
14. Kumar PP, Stotz SC, Paramashivappa R, Beedle AM, Zamponi GW, Rao AS. Synthesis and evaluation of a new class of nifedipine analogs with T-type calcium channel blocking activity. Mol Pharmacol 2002; 61:649-658.
15. Romanin C, Seydl K, Glossmann H, Schindler H. The dihydropyridine niguldipine inhibits T-type Ca2\+ currents in atrial myocytes. Pflugers Arch 1992; 420:410-412.
16. Furukawa T, Nukada T, Namiki Y, Miyashita Y, HatsunoK, Ueno Y,et al. Five different profiles of dihydropyridines in blocking T-type Ca(2\+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes. Eur J Pharmacol 2009; 613:100-107.
17. Furukawa T, Nukada T, Miura R, Ooga K, Honda M, Watanabe S, et al. Differential blocking action of dihydropyridine Ca2\+ antagonists on a T-type Ca2\+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45:241-246.
18. Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008; 73:826-834.
19. Horiba M, Muto T, Ueda N, Opthof T, Miwa K, Hojo M, et al. T-type Ca2\+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2\+ channel blockers. Life Sci 2008; 82:554-560.
20. Okayama S, Imagawa K, Naya N, Iwama H, Somekawa S, Kawata H, et al. Blocking T-type Ca2\+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006; 29:493-497.
21. Takebayashi S, Li Y, Kaku T, Inagaki S, Hashimoto Y, Kimura K, et al. Remodeling excitation-contraction coupling of hypertrophied ventricular myocytes is dependent on T-type calcium channels expression. Biochem Biophys Res Commun 2006; 345:766-773.
22. Izumi T, Kihara Y, Sarai N, Yoneda T, Iwanaga Y, Inagaki K, et al. Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro. Circulation 2003; 108:2530-2535.
23. Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K, et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008; 173:358-369.
24. Xu J, Nagata K, Obata K, Ichihara S, Izawa H, Noda A, et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005; 46:719-724.
25. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006; 47:770-779.
26. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94:1533-1542.
27. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007; 49:1120-1127.
28. Mundhenke M, Schwartzkopff B, Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch 1997; 431:265-273.
29. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93:1074-1081.
30. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446:444-448.
31. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399:601-605.
32. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399:597-601.
33. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101:2567-2578.
34. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51:742-748.
35. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47:656-664.
36. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005; 112:2940-2945.
37. Marcus ML, Koyanagi S, Harrison DG, Doty DB, Hiratzka LF, Eastham CL. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med 1983; 75:62-66.
38. Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990; 15:528-533.
39. Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci 2005; 12:409-420. (Pubitemid 40897646)
40. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001; 98:5780-5785.
41. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005; 111:2073-2085.
42. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation 1999; 99:2396-2401.
43. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2:534-539.
44. Nayler WG, Yepez CE, Poole-Wilson PA. The effect of beta-adrenoceptor and Ca2\+ antagonist drugs on the hypoxia-induced increased in resting tension. Cardiovasc Res 1978; 12:666-674.
45. De Bruyne B, Bronzwaer JG, Heyndrickx GR, Paulus WJ. Comparative effects of ischemia and hypoxemia on left ventricular systolic and diastolic function in humans. Circulation 1993; 88:461-471.